Abstract
Curcumin (1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) is commonly used as a spice, food additive or dietary pigment. Accumulating evidence suggests that curcumin has several pharmacologic effects, including anti-inflammatory, anti-oxidant and anti-cancer activities. The molecular mechanisms underlying the targets of curcumin are diverse and involve combinations of multiple signaling pathways, including NF-κB and STAT3 signaling. Thus, curcumin is one of the most promising phytochemicals that target various cancers and inflammation-mediated diseases. Clinical trials have been ongoing or completed for various cancers, including breast, pancreatic and colorectal cancers, and multiple myeloma. In this review, the molecular mechanisms and the issue of bioavailability are mainly discussed.
Keywords: Bioavailability, cancer, curcumin, inflammation, NF-κB, rupture.
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:Curcumin Targets in Inflammation and Cancer
Volume: 15 Issue: 2
Author(s): Atsuko Deguchi
Affiliation:
Keywords: Bioavailability, cancer, curcumin, inflammation, NF-κB, rupture.
Abstract: Curcumin (1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) is commonly used as a spice, food additive or dietary pigment. Accumulating evidence suggests that curcumin has several pharmacologic effects, including anti-inflammatory, anti-oxidant and anti-cancer activities. The molecular mechanisms underlying the targets of curcumin are diverse and involve combinations of multiple signaling pathways, including NF-κB and STAT3 signaling. Thus, curcumin is one of the most promising phytochemicals that target various cancers and inflammation-mediated diseases. Clinical trials have been ongoing or completed for various cancers, including breast, pancreatic and colorectal cancers, and multiple myeloma. In this review, the molecular mechanisms and the issue of bioavailability are mainly discussed.
Export Options
About this article
Cite this article as:
Deguchi Atsuko, Curcumin Targets in Inflammation and Cancer, Endocrine, Metabolic & Immune Disorders - Drug Targets 2015; 15 (2) . https://dx.doi.org/10.2174/1871530315666150316120458
DOI https://dx.doi.org/10.2174/1871530315666150316120458 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Modulation of Cellular Response to Anticancer Treatment by Caffeine: Inhibition of Cell Cycle Checkpoints, DNA Repair and More
Current Pharmaceutical Biotechnology Development of Genetic Testing for Breast, Ovarian and Colorectal Cancer Predisposition: A Step Closer to Targeted Cancer Prevention
Current Drug Targets Anticancer Drug-Induced Immunomodulation and Cancer Therapeutics
Current Cancer Therapy Reviews Carbon Nanotubes – Curse or Blessing
Current Medicinal Chemistry Adenoviral Vectors for Cancer Gene Therapy
Current Genomics “Metabolic Reprogramming” in Ovarian Cancer Cells Resistant to Cisplatin
Current Cancer Drug Targets ErbB4 and its Isoforms: Patentable Drug Targets?
Recent Patents on DNA & Gene Sequences Antioxidant Response of Osteoblasts to Doxycycline in an Inflammatory Model Induced by C-reactive Protein and Interleukin-6
Infectious Disorders - Drug Targets Mesothelioma - Update on Management
Current Respiratory Medicine Reviews Implication of Prophetic Variables and their Impulsive Interplay in CA Prostate Patients Experiencing Osteo-Metastasis
Anti-Cancer Agents in Medicinal Chemistry Jatrorrhizine Protects Against Okadaic Acid Induced Oxidative Toxicity Through Inhibiting the Mitogen-Activated Protein Kinases Pathways in HT22 Hippocampal Neurons
CNS & Neurological Disorders - Drug Targets Genetic Predisposition to Neonatal Tumors
Current Pediatric Reviews Phosphatidylinositol 3-Kinase Isoforms as Novel Drug Targets
Current Drug Targets P-glycoprotein Inhibition as a Therapeutic Approach for Overcoming Multidrug Resistance in Cancer: Current Status and Future Perspectives
Current Cancer Drug Targets An Efficient Cancer Classification Model for CT/MRI/PET Fused Images
Current Medical Imaging Gene Therapy Approaches for the Selective Killing of Cancer Cells
Current Pharmaceutical Design Role of Angiopoietin-like 4 (ANGPTL4), a Member of Matricellular Proteins: from Homeostasis to Inflammation and Cancer Metastasis
Current Angiogenesis (Discontinued) YB-1 Activities in Oncogenesis: Transcription and Translation
Current Cancer Therapy Reviews Targeting Transcription Factors for Cancer Gene Therapy
Current Gene Therapy CD248: Reviewing its Role in Health and Disease
Current Drug Targets